Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2023-04-20 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
安信证券股份有限公司关于奥锐特药业股份有限公司2022年度持续督导报告书
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度持续督导报告书" which translates to "2022 Annual Continuous Supervision Report" by the sponsor (安信证券股份有限公司) for 奥锐特药业股份有限公司. It references regulatory requirements from the China Securities Regulatory Commission and Shanghai Stock Exchange rules regarding continuous supervision after the company's IPO. The content details the sponsor's ongoing supervisory activities, compliance checks, internal control reviews, and information disclosure oversight during the year 2022. It is not a full annual report or financial statement but a regulatory compliance and supervision report by the sponsor. This type of document fits the category of Audit Report / Information (AR), as it is a standalone report related to regulatory supervision and compliance, not the company's own annual report or earnings release. The document length (8604 characters) and detailed supervisory content support this classification rather than a brief announcement or a report publication notice. FY 2022
2023-04-20 Chinese
国浩律师（杭州）事务所关于奥锐特药业股份有限公司 2023年第一次临时股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, voting procedures, and results of a company's 2023 first extraordinary general meeting (临时股东大会). It details the legality and validity of the meeting's procedures and resolutions, including approval of convertible bond issuance and related matters. The document is not a financial report, earnings release, or management discussion, but a legal opinion on the shareholder meeting and its voting results. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results of the shareholders' meeting. The document length is substantial and contains detailed voting results and legal opinions on the meeting's validity, not just an announcement of a meeting or report publication. Therefore, the correct classification is DVA with high confidence.
2023-04-19 Chinese
奥锐特药业股份有限公司2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 first extraordinary shareholders' meeting of 奥锐特药业股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals related to convertible bond issuance, and legal witness statements confirming the validity of the meeting and resolutions. The content focuses on the official voting results and decisions made by shareholders during the meeting, rather than presenting a report or financial statements. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is sufficient and contains substantive voting details, not just a brief announcement or a report publication notice.
2023-04-19 Chinese
奥锐特药业股份有限公司关于召开2022年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a 2022 annual performance explanation meeting (业绩说明会) by 奥锐特药业股份有限公司. It provides details on the meeting time, location, format (video and online interaction), and how investors can participate and ask questions. It references that the 2022 annual report has already been published on April 15, 2023, and this meeting is to explain and discuss the results. The document does not contain actual financial data or detailed financial analysis but is an announcement of an upcoming investor presentation event focused on financial results and company performance. Therefore, it fits the category of Investor Presentation (IP) rather than the Annual Report (10-K) or Earnings Release (ER). The document length is short (1444 characters), and it is clearly an announcement of a meeting rather than the meeting content or transcript itself, but since it is about an investor-focused presentation of financial results, the best fit is Investor Presentation (IP).
2023-04-19 Chinese
奥锐特药业股份有限公司独立董事候选人声明（钟永成）
Board/Management Information Classification · 95% confidence The document is a declaration statement by an independent director candidate, detailing qualifications, independence criteria, and compliance with regulatory requirements. It is a formal statement related to board membership candidacy rather than a report, announcement of voting results, or management change notice. It does not contain financial data, audit information, or meeting materials. The content fits best under Board/Management Information (MANG) as it pertains to board member nomination and qualifications.
2023-04-14 Chinese
奥锐特药业股份有限公司关于公司2022年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's 2022 annual fundraising (募集资金) storage and actual usage situation. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding the management and use of raised funds. The document includes specific financial figures about the amount raised, usage, balance, and compliance with regulatory requirements. It also contains auditor and sponsor institution opinions on the fundraising usage. The content is focused on the management and use of capital raised through equity issuance, not a general financial report or earnings release. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is sufficient and contains substantive financial data related to fundraising usage, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2023-04-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.